Clinical Trial Update: An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR) [EARLY_Phase 1]

View source ↗

Summary

An early-phase open-label, double-blind discontinuation study of quetiapine XR for social anxiety disorder; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Social Anxiety Disorder

Drugs mentioned

• Quetiapine XR Extended Release (Quetiapine)

Snippet

Sponsor: Duke University | Conditions: Social Anxiety Disorder | EARLY_Phase 1 | Status: TERMINATED